Medical disclaimer (please read): This article is for general education and is not medical advice. It does not replace care from a licensed clinician who knows your medical history. Never start, stop, or change a medication based on something you read online. If you think you may have a medication side effect or emergency, seek urgent care or call 911.

Retatrutide has become one of the most talked-about investigational “next generation” weight-loss medications in the United States. The reason is simple: in early research, it produced very large average weight loss—in some participants approaching the kind of results historically seen only with bariatric surgery—while being taken as a once-weekly injection.

At the same time, retatrutide is still being studied. That means there are important unknowns: who benefits most, what the long-term safety profile looks like, how durable weight loss is after stopping, and how it compares head-to-head with currently available FDA-approved medications.

This guide explains retatrutide in plain language, summarizes what we know from published clinical trials (including the pivotal phase 2 obesity trial), reviews key safety considerations, and offers a realistic timeline for when it might become available in the US—without hype, and without overpromising.

Quick takeaways (for skimming)

Retatrutide is investigational (not FDA-approved for weight loss in the US as of this writing).
It is a triple-hormone receptor agonist: it activates GIP, GLP-1, and glucagon receptors. (You may hear it described as a “triple agonist.”)
In a phase 2 trial in adults with obesity or overweight with comorbidities, retatrutide produced dose-dependent weight loss at 24 weeks and 48 weeks. The highest dose group averaged about 24% weight loss at 48 weeks in that study.
Common side effects were gastrointestinal (nausea, vomiting, diarrhea, constipation, abdominal discomfort), similar to the GLP-1 medication family. These were generally mild-to-moderate but were dose-related.
Heart rate increased in a dose-related pattern in the phase 2 study, peaking around 24 weeks and then declining.
Access in the US is mainly through clinical trials. The FDA has also stated that retatrutide cannot be used in compounding under federal law and is not a component of an FDA-approved drug.
If phase 3 trials confirm benefits and safety, a manufacturer could submit for FDA approval, but exact timing is uncertain and depends on trial timelines, results, and FDA review.

1) What is retatrutide?

Retatrutide (LY3437943) is an investigational medication being studied for chronic weight management and related health conditions. It is given as a subcutaneous injection (under the skin), typically once weekly in clinical trials.

What makes retatrutide different from many current weight-loss injections is that it targets three hormone signaling pathways that influence appetite, satiety, glucose metabolism, and energy balance.

Retatrutide vs. “GLP-1s”: what’s the difference?

Many people are familiar with GLP-1 receptor agonists used for diabetes and weight loss (for example, semaglutide). Another newer medication for weight loss, tirzepatide, targets two pathways (often described as dual GIP/GLP-1 activity).

Retatrutide is often described as a triple agonist because it activates:

GLP-1 receptor
GIP receptor
Glucagon receptor

Researchers are studying whether this “triple” activity can improve:

the magnitude of weight loss,
metabolic improvements (blood sugar, lipids),
and possibly energy expenditure—while still being tolerable and safe.

What are GLP-1, GIP, and glucagon (in plain English)?

These hormones are part of your body’s system for managing:

how hungry you feel,
how full you feel after eating,
how your body handles glucose (blood sugar),
and how energy is used or stored.

A simplified way to think about them:

GLP-1 signaling tends to reduce appetite, slow stomach emptying, and improve glucose control.
GIP signaling interacts with insulin secretion and may influence appetite and fat metabolism; it’s complex, but it appears to add benefit in combination with GLP-1 activity for some medications.
Glucagon signaling is known for raising blood sugar in classic physiology, but in carefully engineered medications it may also influence energy expenditure and fat metabolism. This is one reason triple-agonist designs are being investigated—though it also raises careful safety questions and is why large phase 3 trials matter.

2) Who is retatrutide being studied for?

Retatrutide has been studied (and is being studied) in adults with:

Obesity (commonly BMI ≥ 30), or
Overweight (BMI ≥ 27) plus at least one weight-related condition

Phase 3 research programs (such as the TRIUMPH program) include participants:

with obesity/overweight without type 2 diabetes,
with type 2 diabetes,
with established cardiovascular disease,
and with certain obesity-associated conditions.

3) What do clinical trials show so far?

Retatrutide’s widely cited weight-loss results come primarily from a phase 2 trial published in a major medical journal. That’s meaningful—but it’s not the same as FDA approval, and it’s not the same as knowing long-term safety over many years.

4) Phase 2 obesity trial results (key numbers)

A pivotal phase 2, randomized, double-blind, placebo-controlled trial evaluated retatrutide in adults with obesity or overweight plus at least one weight-related condition.

Weight loss at 24 weeks (primary endpoint)

At 24 weeks, the least-squares mean percent change in body weight was:

-7.2% (1 mg)
-12.9% (combined 4 mg groups)
-17.3% (combined 8 mg groups)
-17.5% (12 mg)
vs -1.6% (placebo)

Weight loss at 48 weeks (secondary endpoint)

At 48 weeks, the least-squares mean percent change in body weight was:

-8.7% (1 mg)
-17.1% (combined 4 mg groups)
-22.8% (combined 8 mg groups)
-24.2% (12 mg)
vs -2.1% (placebo)

How many people hit “meaningful” milestones?

At 48 weeks, the proportion achieving specific weight loss thresholds was reported as:

4 mg: ≥5% in 92%, ≥10% in 75%, ≥15% in 60%
8 mg: ≥5% in 100%, ≥10% in 91%, ≥15% in 75%
12 mg: ≥5% in 100%, ≥10% in 93%, ≥15% in 83%
placebo: ≥5% in 27%, ≥10% in 9%, ≥15% in 2%

5) Safety and side effects: what we know, what we don’t

The most common side effects: gastrointestinal (GI)

In the phase 2 trial, the most common adverse events were gastrointestinal, and they were dose-related.

Heart rate changes

The phase 2 trial reported dose-dependent increases in heart rate that peaked at 24 weeks and declined thereafter.

6) Important US consumer safety note: compounded or “research” retatrutide products

The FDA has explicitly addressed this and notes retatrutide is not FDA-approved and cannot be used in compounding under federal law.

7) When might retatrutide be available in the US?

Retatrutide remains investigational in the United States. If phase 3 trials confirm benefits and safety, the manufacturer could submit for FDA approval, but the exact timing is uncertain.

8) How to find legitimate clinical trials (US)

Start with ClinicalTrials.gov and search for:

“retatrutide”
“LY3437943”

Bring the trial listing to your clinician to discuss whether participation is safe and sensible for you.

9) FAQ

Is retatrutide FDA-approved for weight loss in the US?

No—not as of 2026-02-02.

Is “compounded retatrutide” safe?

FDA warns about unapproved GLP-1-type products and states retatrutide cannot be used in compounding under federal law.

References (reputable sources)

Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine (2023). https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
PubMed record: https://pubmed.ncbi.nlm.nih.gov/37366315/
ClinicalTrials.gov NCT04881760: https://clinicaltrials.gov/study/NCT04881760
FDA: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
NIDDK obesity meds: https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity